Henry Meds vs IVIM Health vs Mochi Health (2026)

On tirzepatide, the order is IVIM Health↗ ($278) → Mochi Health↗ ($278) → Henry Meds↗ ($349) — gaps of $0 and then $71 a month, a $852 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

IVIM Health: the record, condensed

On tirzepatide, the number that matters at IVIM Health is $278 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Note the shape: $208 is the number in the marketing, $278 is the number at maintenance. The $70 difference is not a fee or a trick per se — it is dose-tiered pricing doing what dose-tiered pricing does — but it means the advertised figure describes month one, not month twelve.

Inside that $278 sits a mandatory $75-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $203, and it is not a price anyone can actually pay, because the membership cannot be declined.

Context for that figure: it ranks #3 of 17 in the verified tirzepatide index — $63/month above the floor (NexLife↗, $215) — and sits $171 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,336.

IVIM Health’s semaglutide program bills $149 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The figure is quoted at maintenance without a separate teaser tier, which keeps the arithmetic honest by default.

Inside that $149 sits a mandatory $75-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $74, and it is not a price anyone can actually pay, because the membership cannot be declined.

To place the number: #3 of 20 verified programs, with the floor $16/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $200 a month. A year at this figure: $1,788 monthly-billed.

Operationally at IVIM Health: shipping included; commitment membership mandatory for duration; cancellation membership mandatory; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the IVIM Health page · visit IVIM Health ↗

Mochi Health: the record, condensed

On tirzepatide, the number that matters at Mochi Health is $278 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Inside that $278 sits a mandatory $79-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $199, and it is not a price anyone can actually pay, because the membership cannot be declined.

To place the number: #4 of 17 verified programs, with the floor $63/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $171 a month. A year at this figure: $3,336 monthly-billed.

Start with the load-bearing figure: $178 a month, all-in, is what Mochi Health charges for semaglutide at the 2.4 mg basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The all-in figure already contains a compulsory $79 monthly membership. That is the honest way to quote it: a bundled price is only misleading when its parts are advertised separately, and here the medication-only $99 would be exactly that kind of mirage.

Context for that figure: it ranks #8 of 20 in the verified semaglutide index — $45/month above the floor (Oak Longevity, $133) — and sits $171 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,136.

Operationally at Mochi Health: shipping included; commitment membership recurs monthly; cancellation cancel membership any time; recurs until cancelled; pharmacy named (company-owned compounding facility); states: most states; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Mochi Health page · visit Mochi Health ↗

Henry Meds: the record, condensed

On tirzepatide, the number that matters at Henry Meds is $349 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $349 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #10 of 17 in the verified tirzepatide index — $134/month above the floor (NexLife, $215) — and sits $100 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,188.

On semaglutide, the number that matters at Henry Meds is $179 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #9 of 20 verified programs, with the floor $46/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $170 a month. A year at this figure: $2,148 monthly-billed.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

§ The three-way read

Prices, gaps, and what sits inside them

IVIM Health holds the low ground at $278 (its $75 membership already inside). Mochi Health follows at $278 (+$0/mo, $0/yr), membership included. Henry Meds tops the trio at $349 (+$71/mo over the leader, $852/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles nothing: IVIM Health $149 → Mochi Health $178 → Henry Meds $179 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: IVIM Health ($278); cheapest 12-month path: IVIM Health ($3,336); simplest billing (no membership): Henry Meds; dose-flat structure: Mochi Health and Henry Meds; named-pharmacy transparency: Mochi Health; cheapest semaglutide of the three: IVIM Health ($149).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: IVIM Health vs Mochi Health · IVIM Health vs Henry Meds · Mochi Health vs Henry Meds.

§ Structure, three ways

Everything besides the three prices

Memberships: IVIM Health $75/mo (inside its figure); Mochi Health $79/mo (inside its figure); Henry Meds none. Structures: IVIM Health step/tiered; Mochi Health dose-flat; Henry Meds dose-flat. Pharmacies: IVIM Health not named; Mochi Health named (company-owned compounding facility); Henry Meds not named. States: IVIM Health — not published; Mochi Health — most states; Henry Meds — most states. Exit terms: IVIM Health — membership mandatory; Mochi Health — cancel membership any time; recurs until cancelled; Henry Meds — check terms before prepaying.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: IVIM Health source-verified (2026-08-05); Mochi Health source-verified (2026-08-05); Henry Meds third-party reported (2026-08-05).

The trio on semaglutide, across time

3 mo: IVIM Health $447 vs Mochi Health $534 vs Henry Meds $537 6 mo: IVIM Health $894 vs Mochi Health $1,068 vs Henry Meds $1,074 12 mo: IVIM Health $1,788 vs Mochi Health $2,136 vs Henry Meds $2,148 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

IVIM Health: $3,336/yr monthly-billed; Mochi Health: $3,336/yr monthly-billed; Henry Meds: $4,188/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $1,704 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

Work it as eliminations rather than a beauty contest. Henry Meds enters owing an explanation: $71/month above IVIM Health compounds to $852 a year — real therapy-months of money — so its record has to name what the premium buys (structure the cheaper two lack) or it exits first. Mochi Health survives the first cut only to face the harder question — whether its dose-flat structure removes titration repricing is worth $0 a month to you — because a middle option that cannot answer it is just the expensive option with better camouflage. IVIM Health is what remains: the arithmetic answer at $278, dethroned only by a state gap, a structural need, or a prescriber’s judgment — the three things this page deliberately cannot decide.

The same trio on best published rate: IVIM Health $278 → Mochi Health $278 → Henry Meds $349 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — IVIM Health $834, Mochi Health $834, Henry Meds $1,047; 6 months — IVIM Health $1,668, Mochi Health $1,668, Henry Meds $2,094. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

Grade the three records before trusting the three prices. On the five-point disclosure checklist (price, pharmacy, states, cancellation, source-verification): IVIM Health 4/5 · Mochi Health 5/5 · Henry Meds 3/5. The gap between Mochi Health (5/5) and Henry Meds (3/5) is itself information: undisclosed axes are where the questions in each provider’s review earn their keep. The concrete splits — pharmacy named: Mochi Health yes, IVIM Health and Henry Meds no — convert directly into pre-purchase emails. Every score is a computation from the dataset, contestable at the corrections desk like any other figure.

The three-way verdict compresses cleanly: IVIM Health is the default on arithmetic; Mochi Health earns the middle only where its structure (membership services) solves something the floor does not; and Henry Meds’s $71/month premium over the leader — $852 a year, roughly 3.1 extra months of therapy at the floor rate — needs a named justification from its record, not a vibe. Insurance coverage, where it exists, outranks all three.